View Author
patient hepatitis hbeag treatment therapy hepatitis b study response level hbeag loss resistance baseline tenofovir lamivudine fi brosis liver tenofovir df hbsag hbv dna hepatology virus adefovir virologic response disease combination brosi university group infection peg-ifn follow-up analysis table virologic cirrhosis 32 weeks hepatitis b virus hbeag-positive genotype hbv infection hbv dna levels month adefovir dipivoxil serum hbv dna level ef ficacy week 32 dipivoxil entecavir hbsag loss etv monotherapy combination therapy journal value result gilead sciences mutation cohort gastroenterology milliliter seroconversion event hbeag-positive patients liver disease score hospital model scenario history hbsag negativity 400 copies burden department lecture fees virologic breakthrough hepatitis b patients monotherapy erasmus university interferon suppression
7 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
(Article)
Petersen, J. Ratziu, V. Berg, T. Sarrazin, C. Lutgehetmann, M. Buggisch, P. Buti, M. Janssen, H.L.A. Brown, A. Lampertico, P. Schollmeyer, J. Zoulim, F. Wedemeyer, H. Sterneck, M. |
2012-03-01
|
|
Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues
(Article)
Reijnders, J.G.P. Deterding, K. Petersen, J. Zoulim, F. Santantonio, T. Buti, M. Bömmel, F. van Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. |
2010-04-01
|
|
Early hbeag loss during peginterferon α-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients
(Article)
Buster, E.H.C.J. Flink, H.J. Hansen, B.E. Janssen, H.L.A. Simsek, H. Heathcote, E.J. Sharmila, S. Kitis, G.E. Gerken, G. Buti, M. Vries, R.A. de Verhey, E. |
2009-10-01
|
|
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
(Article)
Marcellin, P. Heathcote, E.J. Manns, M.P. Kotzev, I. Tchernev, K. Buggisch, P. Weilert, F. Kurdas, O.O. Shiffman, M.L. Trinh, H. Washington, M.K. Sorbel, J. Buti, M. Anderson, J. Snow-Lampart, A. Mondou, E. Quinn, J. Rousseau, M.F. Gane, E. Man, R.A. de Krastev, Z. Germanidis, G. Lee, S.S. Flisiak, R. Kaita, K. |
2008-12-04
|
|
Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain
(Article)
Idris, B.I. Brosa, M. Richardus, J.H. Esteban, R. Schalm, S.W. Buti, M. |
2008-04-01
|
|
Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
(Article)
Buster, E.H.C.J. Hansen, B.E. Buti, M. Delwaide, J. Niederau, C. Michielsen, P.P. Flisiak, R. Zondervan, P.E. Schalm, S.W. Janssen, H.L.A. |
2007-08-01
|
